ANAPTYSBIO, INC entered into Sublease Agreement with First Tracks Biotherapeutics, Inc. valued at monthly rent equal to the monthly Basic Rent and Additional Rent owed by the Company under the Maste (effective 2026-06-15).
“On June 15, 2026, AnaptysBio, Inc. (the “Company”), entered into a Sublease Agreement (the “Sublease”) with First Tracks Biotherapeutics, Inc., a Delaware corporation (“First Tracks”), pursuant to which the Company agreed to sublease to First Tracks approximately 45,057 rentable square feet of space located at 10770 Wateridge Circle, San Diego, California 92121 (the “Premises”).”
Governance Changes
ANAPTYSBIO, INC: Changed fiscal year-end from December 31 to June 30, effective July 1, 2026 (effective 2026-07-01).
“On May 18, 2026, the Board of Directors of AnaptysBio, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from December 31 to June 30.”
Earnings Releases
ANAPTYSBIO, INC reported first quarter ended March 31, 2026 results: revenue Collaboration revenue was $25.6 million for the three months ended March 31, 2026, net income Net loss was $52.9 million for the three months ended March 31, 2026, or a net loss per share of $1.84, EPS net loss per share of $1.84.
“On May 12, 2026, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months ended March 31, 2026.”
Christopher M. Murphy was appointed as Chief Financial Officer at ANAPTYSBIO, INC.
“On May 11, 2026, AnaptysBio, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Christopher M. Murphy as Chief Financial Officer, effective as of May 11, 2026.”
Material Agreements
ANAPTYSBIO, INC entered into Separation and Distribution Agreement with First Tracks Biotherapeutics valued at $100.0 million.
“the Company and First Tracks Biotherapeutics entered into a separation and distribution agreement (the “Separation and Distribution Agreement”)”
M&A Transactions
ANAPTYSBIO, INC completed a disposition involving First Tracks Biotherapeutics, Inc. (closed 2026-04-20).
“completed the previously announced separation (the "Spin-Off") of First Tracks Biotherapeutics, Inc. ("First Tracks Biotherapeutics") from the Company”
“As previously disclosed, on November 5, 2024, the Company entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (the “Agent”), pursuant to which the Company could issue and sell, from time to time, shares of its common stock, par value $0.001 per share (the “Common Shares”), up to an aggregate offering price equal to the Maximum Amount (the “ATM Program”). The Company has issued a termination letter to the Agent to terminate the Sales Agreement.”
Material Agreements
ANAPTYSBIO, INC entered into Purchase Agreement with certain third party investors valued at approximately $80 million (effective 2026-03-26).
“On March 26, 2026, First Tracks Biotherapeutics and EcoR1 Capital Fund Qualified, L.P. (the “Selling Stockholder”) entered into a purchase agreement (the “Purchase Agreement”) with certain third party investors (collectively, the “Investors”), pursuant to which SpinCo agreed to issue and sell an aggregate 5,791,478 shares of SpinCo’s common stock”
Earnings Releases
ANAPTYSBIO, INC reported first quarter ended March 31, 2024 results: revenue $7.2 million.
“activities as well as a one-time non-operating cash payment of $10.9 million during the quarter. ◦ Reiterating cash runway through year-end 2026 • Collaboration revenue was $7.2 million for the three months ended March 31, 2024, compared to $1.4 million for the three months ended March 31, 2023. The change is due primarily to increased royalties”
Earnings Releases
ANAPTYSBIO, INC reported financial results for the fourth quarter and year ended December 31, 2023.
“On March 11, 2024, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months and year ended December 31, 2023.”
Material Agreements
ANAPTYSBIO, INC entered into License Agreement with Centessa Pharmaceuticals (UK) Limited valued at $7 million (effective 2023-11-24).
“On November 24, 2023, AnaptysBio, Inc. (“ Anaptys ”) entered into a License Agreement (the “ License Agreement ”) with Centessa Pharmaceuticals (UK) Limited (“ Centessa ”) pursuant to which Centessa granted to Anaptys an exclusive worldwide license under Centessa’s rights to the blood dendritic cell antigen 2 (BDCA2) modulator antibody portfolio, including lead asset CBS004 and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases.”
John Orwin was appointed as Chairman at ANAPTYSBIO, INC.
“On September 15, 2023, the Board appointed John Orwin as a Class II director, a member of the Nominating and Corporate Governance Committee and Chairman of the Board, effective immediately.”
James N. Topper resigned as Chairman at ANAPTYSBIO, INC.
“On September 14, 2023, James N. Topper, M.D., Ph.D., advised the Board of Directors (the “ Board ”) of AnaptysBio, Inc. (the “ Company ”) that he would resign as a Class II director and as Chairman of the Board, effective on September 15, 2023.”
Earnings Releases
ANAPTYSBIO, INC reported financial results for second quarter ended June 30, 2023.
“On August 7, 2023, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.”
Shareholder Votes
ANAPTYSBIO, INC shareholders approved Approval of the Amended and Restated Certificate of Incorporation permitting the exculpation of officers at the 2023-06-15 meeting.
“4. Approval of the Amended and Restated Certificate of Incorporation permitting the exculpation of officers: Shares For Shares Against Shares Withheld/Abstaining Broker Non-Votes 21,803,870 605,555 407 2,247,178”
Shareholder Votes
ANAPTYSBIO, INC shareholders approved Non-binding, advisory approval of compensation paid to the Company's named executive officers at the 2023-06-15 meeting.
“3. Non-binding, advisory approval of compensation paid to the Company’s named executive officers: Shares For Shares Against Shares Withheld/Abstaining Broker Non-Votes 15,221,869 7,185,726 2,237 2,247,178”
Shareholder Votes
ANAPTYSBIO, INC shareholders approved Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-15 meeting.
“2. Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: Shares For Shares Against Shares Withheld/Abstaining Broker Non-Votes 24,453,643 203,193 174 —”
Shareholder Votes
ANAPTYSBIO, INC shareholders approved Election of three Class III directors, Magda Marquet, Ph.D., Hollings Renton, M.B.A., and John P. Schmid, each to serve a three-year term at the 2023-06-15 meeting.
“1. Election of three Class III directors, Magda Marquet, Ph.D., Hollings Renton, M.B.A., and John P. Schmid, each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders or until such time as his or her respective successor has been duly elected and qualified or until such director’s earlier resignation or removal: Nominees Shares For Shares Withheld / Abstaining Broker Non-Votes Magda Marquet, Ph.D. 21,553,117 856,715 2,247,178 Hollings Renton, M.B.A. 16,883,226 5,526,606 2,247,178 John P. Schmid 20,391,333 2,018,499 2,247,178”
Earnings Releases
ANAPTYSBIO, INC reported financial results for the three months ended March 31, 2023.
“On May 11, 2023, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months ended March 31, 2023.”
Rita Jain was appointed as Class II director and member of Compensation Committee at ANAPTYSBIO, INC.
“On April 3, 2023, the Board appointed Rita Jain, M.D. as a Class II director and as a member of the Compensation Committee, effective immediately.”
Laura J. Hamill resigned as Class II director at ANAPTYSBIO, INC.
“On April 1, 2023, Laura J. Hamill advised the Board of Directors (the “ Board ”) of AnaptysBio, Inc. (the “ Company ”) that she would resign as a Class II director of the Board, effective on April 1, 2023 (the “ Resignation ”).”
Earnings Releases
ANAPTYSBIO, INC reported financial results for the three months and year ended December 31, 2022.
“On March 1, 2023, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months and year ended December 31, 2022.”
Governance Changes
ANAPTYSBIO, INC: Adoption of second amended and restated bylaws with changes related to universal proxy rules, DGCL amendments, advance notice provisions, emergency bylaws, and exclusive forum for Securities Act claims (effective 2023-02-07).
“approved and adopted the Company’s second amended and restated bylaws”
Earnings Releases
ANAPTYSBIO, INC reported financial results for three and nine months ended September 30, 2022.
“On November 8, 2022, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.”
Daniel Faga was appointed as Interim President and Chief Executive Officer at ANAPTYSBIO, INC.
“the Company appointed Daniel Faga, a Class I director of the Board, to serve as Interim President and Chief Executive Officer of the Company, effective as of March 21, 2022.”
Hamza Suria resigned as President and Chief Executive Officer at ANAPTYSBIO, INC.
“On March 20, 2022, Hamza Suria, provided notice to the board of directors (the “Board”) of AnaptysBio, Inc. (the “Company”) of his resignation as President and Chief Executive Officer and as a Class II director of the Company, effective immediately.”
Daniel Faga was appointed as Class I Director at ANAPTYSBIO, INC.
“On November 26, 2021, AnaptysBio, Inc. (the “Company”) appointed Mr. Daniel Faga, as a Class I director on its board of directors (the “Board”), effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.